This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Vita Genomics, Inc.. Active years: 2006-2008.
Company Filing History:
Years Active: 2006-2008
Title: Yuchi Hwang: Innovator in Liver Disorder Therapies
Introduction
Yuchi Hwang is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of medical research, particularly in the area of liver disorders. With a total of 2 patents, Hwang's work focuses on improving treatment outcomes for patients suffering from hepatitis C virus (HCV) infections.
Latest Patents
Hwang's latest patents include groundbreaking methodologies aimed at enhancing therapeutic responses for liver disorders. One of his notable inventions is a set of nucleic acids and methods for predicting a subject's responsiveness to therapy for liver disorders. This innovation is crucial for tailoring treatments to individual patients, thereby increasing the efficacy of medical interventions. Another significant patent involves a method for detecting an individual's propensity to respond effectively to a combined therapy of interferon-α and ribavirin. This invention provides isolated polynucleotides that include sequences from the genomic region around the CD81 gene, which are associated with treatment responses in HCV patients.
Career Highlights
Yuchi Hwang is currently affiliated with Vita Genomics, Inc., where he continues to advance research in genomics and therapeutic applications. His work has been instrumental in developing predictive tools that can guide treatment decisions for HCV patients, ultimately improving patient care and outcomes.
Collaborations
Hwang collaborates with esteemed colleagues, including Kuang-Den Chen and Jui-Lin Chen. Their combined expertise fosters an innovative environment that drives research forward in the field of liver disorders.
Conclusion
Yuchi Hwang's contributions to the medical field, particularly in liver disorder therapies, highlight his role as a leading inventor. His patents not only reflect his innovative spirit but also promise to enhance treatment strategies for patients worldwide.